Capmatinib Withdrawn Phase 2 Trials for Carcinoma NOS / Non-Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03240393Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)